---
figid: PMC6858516__nihms-1054030-f0003
figtitle: Towards precision oncology in advanced prostate cancer
organisms:
- Homo sapiens
- Mus musculus
- NA
pmcid: PMC6858516
filename: nihms-1054030-f0003.jpg
figlink: /pmc/articles/PMC6858516/figure/F3/
number: F3
caption: Genomic alterations involving the PTEN-PI3K-AKT pathway occur in ~50% of
  metastatic castration-resistant prostate cancers (mCRPCs) resulting in PI3K-AKT
  pathway activation. Loss of PTEN has been associated with shorter time on androgen
  receptor (AR) pathway inhibitor (ARPI) treatment potentially due to reciprocal negative
  feedback of the PI3K and AR signalling pathways. Drugs that target AKT or PI3K inhibitors
  are currently being tested in clinical trials as monotherapy (for AKT-mutated tumours)
  or in combination with ARPIs. A, androgen; ABI, abiraterone; AKTi, AKT inhibitor;
  FKBP5, FK506 binding protein 5; PHLPP, PH domain leucine-rich repeat protein phosphatase;
  Ptdlns(4,5)P2, phosphatidylinositol 4,5-bisphosphate; Ptdlns(3,4,5)P3, phosphatidylinositol
  3,4,5-trisphosphate; RTK, receptor tyrosine kinase.
papertitle: Towards precision oncology in advanced prostate cancer.
reftext: Sheng-Yu Ku, et al. Nat Rev Urol. ;16(11):645-654.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9765834
figid_alias: PMC6858516__F3
figtype: Figure
organisms_ner:
- Homo sapiens
- Mus musculus
redirect_from: /figures/PMC6858516__F3
ndex: 71282ee3-debf-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6858516__nihms-1054030-f0003.html
  '@type': Dataset
  description: Genomic alterations involving the PTEN-PI3K-AKT pathway occur in ~50%
    of metastatic castration-resistant prostate cancers (mCRPCs) resulting in PI3K-AKT
    pathway activation. Loss of PTEN has been associated with shorter time on androgen
    receptor (AR) pathway inhibitor (ARPI) treatment potentially due to reciprocal
    negative feedback of the PI3K and AR signalling pathways. Drugs that target AKT
    or PI3K inhibitors are currently being tested in clinical trials as monotherapy
    (for AKT-mutated tumours) or in combination with ARPIs. A, androgen; ABI, abiraterone;
    AKTi, AKT inhibitor; FKBP5, FK506 binding protein 5; PHLPP, PH domain leucine-rich
    repeat protein phosphatase; Ptdlns(4,5)P2, phosphatidylinositol 4,5-bisphosphate;
    Ptdlns(3,4,5)P3, phosphatidylinositol 3,4,5-trisphosphate; RTK, receptor tyrosine
    kinase.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ERBB2
  - ERBB3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - LYVE1
  - AR
  - PTEN
  - MTOR
  - RPTOR
  - AKT1
  - AKT2
  - AKT3
  - PHLPP1
  - FKBP5
  - Erbb2
  - Erbb3
  - Pik3r1
  - Ar
  - Pten
  - Akt1
  - Phlpp1
  - Fkbp5
  - Ptdlns(4,5)P
  - PtdIns(3,4,5)P
---
